Changes in oxytocin and vasopressin content in posterior pituitary and hypothalamus following pantethine treatment.
Pantethine, a cysteamine precursor, depletes somatostatin in the cerebral cortex and hypothalamus and prolactin in the anterior pituitary and hypothalamus. This study investigated the effect of pantethine on oxytocin and arginine vasopressin content in the posterior pituitary and hypothalamus. Male Long-Evans rats were injected intraperitoneally with escalating doses of pantethine (i.e., 146.7 mg, 293.4 mg and 586.6 mg/100 gm body weight). Hormone content was determined by radioimmunoassay. Three hours after pantethine treatment, the oxytocin content in the posterior pituitary and the hypothalamus was markedly reduced with all doses of the drug. Vasopressin content in the posterior pituitary and hypothalamus was decreased but to a lesser extent than oxytocin and only with the highest dose of pantethine. Pantethine may act to reduce oxytocin and vasopressin content through intracellular conversion to cysteamine. The exact mechanism of action of pantethine on oxytocin and vasopressin remains to be elucidated.
Department of Biological Sciences, St John's University, Jamaica, New York 11439.
G L
GL
Ong
C
C
Miaskowski
J
J
Haldar
D000704:Analysis of Variance; D000818:Animals; D007031:Hypothalamus / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D010121:Oxytocin / Q000378:metabolism*; D010204:Pantetheine / Q000031:analogs & derivatives / Q000494:pharmacology*; D010904:Pituitary Gland, Posterior / Q000187:drug effects* / Q000378:metabolism; D011863:Radioimmunoassay; D051381:Rats; D011919:Rats, Inbred Strains; D013438:Sulfhydryl Compounds / Q000494:pharmacology*; D014667:Vasopressins / Q000378:metabolism*
D013438:Sulfhydryl Compounds; D014667:Vasopressins; D010204:Pantetheine; D010121:Oxytocin; C005425:pantethine